1.Effect of Xingnaojing Injections Combined with Edaravone in the Treatment of Acute Cerebral Hemor-rhage
Qingzuan KONG ; Guangchou CHEN ; Jiuzuo LIN ; Rimin YUAN ; Xiangfu CHEN
China Pharmacist 2014;(11):1896-1897,1900
Objective:To observe the effect of Xingnaojing injections combined with edaravone in the treatment of acute cerebral hemorrhage. Methods:The patients with acute cerebral hemorrhage were randomly divided into the observation group and the control group with 44 cases in each. The two groups were both given conventional treatment. The control group was treated with 30mg edara-vone injections in 0. 9% 500ml sodium chloride infusions, ivd (infused in 30min), bid, while the observation group was additionally given 10ml Xingnaojing injections in 5. 0% 250ml glucose infusions, ivd, qd. After the 4-week treatment, NIHSS score, GCS score, brain edema and hematoma volume, the levels of high sensitive C reactive protein (hs-CRP) and interleukin-6 (IL-6) before and after the treatment in the two groups were observed and compared, and adverse drug reactions were also recorded. Results: After the treat-ment, GCS score was significantly improved (P<0. 05) and NIHSS score was decreased significantly (P<0. 05) in the two groups, and the observation group was better than the control group (P<0. 05). After the treatment, cerebral edema and hematoma volume was notable reduced in the two groups (P<0. 05), while the difference between the two groups was not statistically significant (P>0. 05). The levels of hs-CRP and IL-6 were decreased significantly after the treatment in the two groups (P<0. 05), and the decrease in the observation group was more significant than that in the control group (P<0. 05). The incidence of adverse reactions in the two groups showed no significant difference (P>0. 05). Conclusion: Compared with edaravone alone, Xingnaojing injections combined with edaravone in the treatment of acute cerebral hemorrhage show more significant efficacy.
2.Gene Cloning and Expression of PACAP and Study of Its Biological Activity
Zheyu CHEN ; Yanfeng CHAI ; Cheng HE ; Changlin LU ; Xiangfu WU
Progress in Biochemistry and Biophysics 2001;28(2):192-197
In order to study the expression and the feasibility of scaled production of neuropeptide in the routine expression system such as E.coli with the pituitary adenylate cyclase activating polypep tide(PACAP) as an example, the following experiments were carried out. First, on the basis of the reported amino acid sequence of PACAP, DNA sequence of PACAP w as deduced and six partially complementary oligonucleotide fragments were design ed. The coding region of PACAP was obtained by renaturing the DNA fragments and ligation and identified by DNA sequencing. The coding region of PACAP was cloned into plasmid pGEX-4T-3 and transformed into E.coli BL21(DE3 ). An expression strain BLPACAP was selected. SDS-PAGE analysis revealed that t he GST-PACAP fusion protein was highly expressed and accumulated to about 30% o f the total bacterial proteins. By affinity chromatography, up to 90% GST-PACAP was purified by one step from bacterial lysate. The purified protein could prom ote neurite outgrowth of PC12 cells and the survival of spinal cord neurons.
3.Relationship of Human AFP Variant Peptide and Carbohydrate Difference and Clinical Diagnosis of Primary Hepatocellular Carcinoma
Baihe ZHANG ; Mengchao WU ; Xiaohua ZHANG ; Han CHEN ; Xiangfu WU
Academic Journal of Second Military Medical University 1981;0(04):-
AFP from fetal serum and serum of patients with primary hepatic cancer were purified by affinity chromatography. Then, the lentil lectin-reactive and nonreactive variants of these purified glycoproteins were prepared by affinity chromatography with immobilized lectin. Glycopeptides and oligosaccharides were prepared from variants by protease treatment and hydrazinolysis, respectively, and subjected to carbohydrate and amino acid analysis. A small difference in the carbohydrate compositions of each variant was observed. Analysis of chemical compositions of AFP variants is useful for the differential diagnosis between benign liver diseases and primary hepatic cancer.
4.Effects of different surgical approaches on Siewert Ⅱ adenocarcinoma of esophagogastric junction
Guoxian GUAN ; Weizhong JIANG ; Xing LIU ; Zhifen CHEN ; Huishan LU ; Xiangfu ZHANG
Chinese Journal of General Surgery 2011;26(9):721-725
ObjectiveTo compare the effects of different surgical approaches on SiewertⅡ (esophageal invasion ≤3 cm) adenocarcinoma of esophagogastric junction.MethodsThis retrospective study included 251 cases of Siewert Ⅱ adenocarcinoma of esophagogastric junction undergoing D2 or D2 + total gastrectomy by transabdominal approach ( TA group, 128 cases) or left thoracoabdominal approach ( LTA group, 123 cases).Operation time,blood loss, extent of esophageal resection, number of lymph nodes dissected,morbidity, mortality and the survival rate were a analyzed between the two groups.ResultsThe 3,5-year overall survival rates were 62. 5%, 39.0% ( TA group) and 54. 9%, 31.9% ( LTA group),respectively (P > 0. 05). Length of esophageal resection in the LTA group were slightly longer than that in the TA group (5. 6 ± 1.1) cm vs. (5.4 ± 1.1 ) cm (P <0. 05), the positive surgical margin between two groups were not statistically different[1.6% ( LTA group) vs. 3. 1% ( TA group), ( P > 0. 05 )]. The mean number of removed lymph node were not significantly different between two groups[23.4 ± 8.7 ( TA group) vs. 23.7 ± 8.4 ( LTA group)], ( P > 0. 05 ). The operation time (227 ± 24) min, blood loss (270 ± 78)ml, and perioperative morbidity( 13.3% ) and mortality( 1.6% ) in TA group was significantly better than the LTA group[(261 ±32) min, (342 ±59)ml, 26.8%, 6.5%](P<0.05).ConclusionsFor Siewert Ⅱ adenocarcinoma at esophagogastric junction (esophageal invasion ≤3 cm) ,total gastrectomy with D2 or D2 + lymph node dissection through the transabdominal approach could achieve curative purposes, with a low morbidity and mortality rate.
5.Relationship between DNA methylation of glucocort icoid receptor gene promotor and glucocorticoid receptor gene mRNA expression in systemic lupus erythematosus patients
Junfen FAN ; Hongbo CHEN ; Hong XIA ; Hongzhen MA ; Xiangfu GAO ; Qiyang SHOU ; Lizong ZHANG ; Yongsheng FAN
Chinese Journal of Rheumatology 2017;21(1):42-45
Objective To investigate the relatio nship between the DNA methylation status of gluco-corticoid receptor (GR) gene promoter and mRNA expression level of GRα gene of peripheral blood mononuclear cells (PBMCs) in patients with systemic lupus erythematosus (SLE). Methods Fifteen new onset SLE patients and fifteen healthy controls were enrolled in this study. The DNA methylation status of GR gene promoter 1 of PBMCs was detected through bisulfite sequencing polymerase chain reaction (PCR). The mRNA expression of GRα, DNA methyltransferases, growth arrest and DNA damage-induced 45α (GADD45α) of PBMCs was detected using the quantitative real-time polymerase chain reaction method. T-test and χ2-test were used to detect the differences between the two groups, Pearson's correlation coefficient was used to analyze the linear correlation between two variables. Results Compared with healthy controls, the mRNA expression of GRα was signi-ficantly declined in SLE patients (10±5, 17±7, t=2.69, P<0.05), and the mRNA expression of DNMT1 and GADD45α was significantly elevated in SLE patients (t=3.11, P<0.05 and t=2.98, P<0.05). The overall mean methylation status of the 142 CpG islands of the four promoters was significantly elevated in SLE patients [(16±8)%vs (11±6)%, t=2.75, P<0.05]. The global methylation status of PBMCs in SLE patients was obviously lower than healthy controls (t=4.39, P<0.05). Conclusion Hypermethylation of GRα promoter may result in GRαgene low expression in PBMCs of patients with SLE.
6.Celecoxib inhibits viability, induces apoptosis and inhibits autophagy in acute myeloid leukemia cell lines HL-60 and HL-60 A
Ying LU ; Xiangfu LIU ; Lingling LIU ; Zhesheng LIN ; Yuchan CHEN ; Baoying FENG ; Xiangzhong ZHANG
Chinese Journal of Pathophysiology 2017;33(1):18-25
AIM:To investigate the effects of celecoxib on viability , apoptosis and autophagy in acute myeloid leukemia (AML) cell lines HL-60 and HL-60A.METHODS:The HL-60 cells and HL-60A cells were cultured with vari-ous concentrations (0, 20, 40, 60, 80 and 100μmol/L) of celecoxib.The inhibitory effect of celecoxib on the cell viabil-ity was evaluated by MTT assay .Apoptosis was analyzed by Annexin-V/PI staining.Apoptosis-related and autophagy-relat-ed proteins were determined by Western blot .RESULTS:IC50 of celecoxib were 49.4 μmol/L, 32.0 μmol/L and 25.1μmol/L for HL-60 cells treated with celecoxib for 24 h, 48 h and 72 h, respectively.For HL-60A cells, the corresponding IC50 were 69.1 μmol/L, 42.5 μmol/L and 29.6 μmol/L, respectively.The results of flow cytometry analysis showed the proportions of Annexin-Ⅴ+PI-, Annexin-Ⅴ+PI+and Annexin-Ⅴ-PI+cells were increased in the HL-60 cells, and those of Annexin-Ⅴ+PI-and Annexin-Ⅴ+PI+cells were increased in the HL-60A cells treated with celecoxib for 24 h. After treated with celecoxib , the induction of apoptosis was observed , the apoptosis-related proteins cleaved caspase-3 and cleaved PARP were upregulated , the autophagy-related proteins LC3 II and P62 were both increased , and mTOR, p-mTOR, 4-EBP and p-4-EBP were not changed , indicating that celecoxib inhibited autophagy in the AML cells without the mTOR pathway involvement .CONCLUSION:Celecoxib inhibits the viability of HL-60 cells and HL-60A cells in a time-and dose-dependent manner by its effects of inducing apoptosis and necrosis .Celecoxib inhibits mTOR-independent autoph-agy in AML cells, indicating a possible way of using celecoxib for enhancing the antitumor activity of therapeutic agents to induce cytoprotective autophagy in the AML cells .
7.Clinical study of atomization inhalation with mixture of baikal skullcap root and lightyellow sophora root for proventing invasive fungal infections on lower respiratory tract infection after chemotherapy
Qun FANG ; Xiangfu GAO ; Xianghong MAO ; Liming LOU ; Lingling ZHANG ; Fulan CHEN ; Min LIN ; Xiaoming CHEN
China Modern Doctor 2015;(12):102-105
[Abstratct] Objective To investigate the preventive effect of atomization inhalation with mixture of baikal skullcap root and light yellow sophora root for proventing invasive fungal infection on lower respiratory tract infection after chemotherapy. Methods A total of 60 cases of patients with lower respiratory tract infections after chemotherapy were selected and randomized into control groups and treatment groups, there were 30 cases in every group, anti-infection was taken in two groups according to drug sensitivity test,atomamdation inhalation with mixture of baikal skullcap root and light yellow sophora root was taken in treatment groups in addition, clinical effect was contrasted, incidence rate and time of fungal infection were contrasted between control group and treatment group,and index of blood gas analysis was contrasted between control group and treatment group after two weeks. Results Clinical efficiency was 86.67% in treatment group and was 70.00% in control group,clinical efficiency was higher in treatment groups than in control group,incidence rate of fungal infection was 6.67% in treatment group and was 23.33% in control group,incidence rate of fungal infection was lower in treatment group than in control goup,time of fungal infection was (11.58±1.31)days in treatment group and was (9.41±1.10)days in control group,time of fungal infect was later in treatment group than that in control group. There were no significant differences of the levels of pH,SaO2,PaCO2 and PaO2 between the two groups before treatment, the levels of pH,SaO2,and PaO2 were higher and PaCO2 was lower in treatment group than that in control goup after treatment. Conclusion Atomization inhalation with mixture of baikal skullcap root and light yellow sophora root could improve clinical curative effect of lower respiratory tract infection after chemotherapy,and im-prove respiratory function,provent invasive fungal infections and has good clinical effect.
8.The theory of emphasizing both muscles and bones in the treatment of lumbar intervertebral disc herniation
Xiangfu WANG ; Wanqian ZHANG ; Huihui ZHENG ; Weiguo CHEN ; Heng ZHAO ; Xiangyu YOU ; Huanying YANG ; Gang ZHENG
International Journal of Traditional Chinese Medicine 2022;44(5):485-488
The theory of "equal stress on bones and muscles" emphasizes that "the tendons bind to the bones, the bones are stretched, the bones are connected, and the bones are fractured. The relationship between bone and soft tissues are important, which is the law of Traditional Chinese Medicine in the treatment of orthopedic diseases. For patients with lumbar disc herniation, the percutaneous intervertebral foraminal technology remodels the disordered internal biological balance of the spine under pathological conditions. Among them, two common clinical minimally invasive approaches under endoscopy are paid attention to soft tissue protection, and active and appropriate functional exercises after surgery, which have become a typical manifestation of the theory of "equal stress on bones and muscles" in modern spinal orthopedic surgery.
9.A multicenter randomized phase II trial of domestic product of nrhTNF in the treatment of non-small cell lung cancer.
Qinghua ZHOU ; Mei HOU ; Lu LI ; Li REN ; Meng QIU ; Yuqiong YANG ; Wenxia HUANG ; Zhen CHEN ; Zhiqiang MENG ; Mingzhi SONG ; Mingzhong LI ; Enxiao LI ; Yi LI ; Yu YAO ; Zhiwen ZHENG ; Xing LIU ; Xiangfu ZHANG ; Huishan LU ; Maohong ZHANG ; Xiuwen WANG ; Xuejun YU
Chinese Journal of Lung Cancer 2003;6(1):42-45
BACKGROUNDTo evaluate and compare the effects and toxicity of the domestic product of nrhTNF combined with chemotherapy in the trial group and chemotherapy alone in the control group in the treatment of patients with non-small cell lung cancer (NSCLC).
METHODSNinety patients with NSCLC in multicenter were randomly devided into trial group and control group. Each group had 45 patients. Chemotherapy with CAP regimen was given for the patients in the trial group. Meanwhile, nrhTNF injection of 4×10⁶U/m ² was also given from the 1st to 7th days, the 11th to 17th days on the chemotherapy course. Twenty-one days were as a cycle, 2 cycles were given each patients. Chemotherapy alone with CAP regimen was given in the control group. The chemothepeutic effects and toxicity were observed and compared between the two groups after the therapy.
RESULTSOf the 90 patients, 3 cases in each group were out of the trial because of economy. The other 84 cases (each group had 42 patients) could be used to analyze and evaluate the clinical effects and toxicity. The response rate of chemotherapy was 47.62% (20/42) in the trial group and 19.05% (8/42) in the control group (P=0.002) respectively. The KPS was 85.02±10.74 in the trial group, and 81.35±9.63 in the control group (P=0.038). No significant difference of degree III+IV toxicity was observed between the trial group and control group (P > 0.05). The side effects related to nrhTNF included slight fever, cold like symptoms, pain, and red and swelling in injection site. All of them were mild and didn't need any treatment and disappeared after the therapy.
CONCLUSIONSThe results demonstrate that the effects of domestic nrhTNF combined with chemotherapy can remarkably higher than that of chemotherapy alone in the treatment of NSCLC. It is able to increase the sensitivity to chemotherapy and improve the quality of life of the patients. The toxicity is also slight and is worth to expand clinical use, so as to further evaluate its effect and toxicity.
10.A multicenter randomized phase III trial of domestic product of rmhTNF in the treatment of non-small cell lung cancer.
Qinghua ZHOU ; Xi YAN ; Li REN ; Lu LI ; Meng QIU ; Yuqiong YANG ; Deyun LUO ; Wenxia HUANG ; Luming LIU ; Zhen CHEN ; Zhiqiang MENG ; Yajie WANG ; Qiang FU ; Yang XU ; Linjun YANG ; Mingzhong LI ; Enxiao LI ; Yi LI ; Yu YAO ; Xiangfu ZHANG ; Xing LIU ; Huishan LU ; Maohong ZHANG ; Xiuwen WANG ; Xuejun YU ; Fengzhan QIN ; Rongsheng ZHENG ; Yuqing CHEN ; Minghong BI
Chinese Journal of Lung Cancer 2003;6(4):264-267
BACKGROUNDTo evaluate and compare the effects and toxicity of the domestic product of recombinant mutant human tumor necrosis factor (rmhTNF) combined with chemotherapy and chemotherapy alone in the treatment of patients with non-small cell lung cancer (NSCLC).
METHODSTwo hundred patients with NSCLC in multicenter were randomly devided into trial group (150 cases) and control group (50 cases). Chemotherapy with CAP regimen was given to the patients. Meanwhile, rmhTNF injection of 4×10⁶U/m² was also given from the 1st to 7th days, the 11th to 17th days on the chemotherapy cycle in the trial group. The control patients received chemotherapy alone. Twenty-one days were as a cycle, 2 cycles were given to each patient. The chemotherapeutic effects and toxicity were observed and compared between the two groups after the therapy.
RESULTSof the 200 patients, 5 cases in the trial group and 3 cases in the control group were out of the trial because of economy. The other 192 cases (145 cases in the trial group and 47 cases in the control group) could be analyzed and evaluated the clinical effects and toxicity. The response rate of chemotherapy was 46.90% (68/145) in the trial group and 17.02% (8/47) in the control group respectively ( P =0.001). The KPS scores was 86.02±9.74 in the trial group, and 80.14±9.10 in the control group ( P =0.025). No significant difference of degree III+IV toxicity was observed between the two groups ( P > 0.05). The side effects related to rmhTNF included slight fever, cold-like symptoms, pain and red and swelling in the injection site. All of them were mild and didn't need any treatment and disappeared after the therapy. There were no severe abnormality of liver and kidney function and ECG in both groups.
CONCLUSIONSThe results demonstrate that the effects of domestic rmhTNF combined with chemotherapy are remarkably higher than that of chemotherapy alone in the treatment of NSCLC. rmhTNF can increase the sensitivity to chemotherapy and improve the quality of life of the patients with slight toxicity. Hence rmhTNF is worth expanding clinical use.